CKD-5 Increase the proportion of persons with diabetes and chronic kidney disease who receive recommended medical treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBS)
About the Data
Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.
Number of persons aged 65 years and over with diabetes and chronic kidney disease who have at least one prescription for ACE and/or ARB
Number of persons aged 65 years and over with diabetes and chronic kidney disease
Medication use is obtained from Part D prescription data in the Medicare 5% sample. The cohort includes general Medicare patients diagnosed with both diabetes and chronic kidney disease in each year, who are aged 65 years and over at the beginning of the year and continuously enrolled in the Medicare inpatient/outpatient and physician/supplier program during the entire year. In 2007–2010, patients are enrolled in Medicare Part D during the entire year. Use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBS) is defined by at least one prescription fill from either drug class during the year.
The United States Renal Data System (USRDS) data, data collection procedures, calculation methods, and other technical information are included in the USRDS Annual Data Report.
Any change to the objective text, baseline, target, target-setting method or data source since the Healthy People 2020 launch.
Additional resources about the objective
More information on the analytic methods used to calculate these rates can be found in Appendix A of the USRDS Annual Data Report Atlas
- U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012